Riskpilot← Back to searchSign inGet full accessM&N Läkarkonsult AB
ABActiveOrg 5592643307Barkbåtsvägen 5Medical specialists activities · NACE 8622Est. 20200 employees
Revenue 2025
SEK 1,2M
0% vs 2024
EBITDA margin
96.5%
0% vs 2024
Equity ratio
87.0%
Financial strength
Net profit 2025
SEK 942K
+4% vs 2024
| Revenue | SEK 1,2M | +0% |
| EBITDA | SEK 1,1M | +0% |
| Net profit | SEK 942K | +4% |
| Total assets | SEK 4M | +0% |
| Equity | SEK 3,5M | +5% |
| Employees | 0 | — |
Legal name
M&N Läkarkonsult AB
Org number
5592643307
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
21 juli 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva medicinsk verksamhet, utveckling, utbildning samt därmed förenlig verksamhet.
Address
Barkbåtsvägen 5
Email
petter_navik@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 120 | 918 | 1 352 | 1 179 | 1 179 |
| Staff expenses | — | −16 | — | −10 | −6 |
| EBITDA | 1 060 | 874 | 1 303 | 1 142 | 1 138 |
| Depreciation & amort. | −0 | — | −0 | — | — |
| EBIT | 1 060 | 874 | 1 303 | 1 142 | 1 138 |
| Net financials | — | 0 | 2 | 4 | 0 |
| Profit before tax | 810 | 875 | 1 305 | 1 146 | 1 188 |
| Tax | −173 | −180 | −270 | −237 | −246 |
| Net profit | 637 | 694 | 1 035 | 910 | 942 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 171 | 1 878 | 3 102 | 3 988 | 3 978 |
| Equity | 662 | 1 356 | 2 390 | 3 300 | 3 462 |
| Long-term debt | 0 | — | 0 | — | — |
| Short-term debt | 259 | 272 | 461 | 438 | 316 |
| Total debt | 259 | 272 | 461 | 438 | 316 |
EBITDA margin
96.5%
This company
15.8%
Market median
+511% vs market
20212025
Equity ratio
87.0%
This company
38.2%
Market median
+128% vs market
20212025
Return on equity
27.2%
This company
18.4%
Market median
+48% vs market
20212025
Net profit margin
79.9%
This company
8.1%
Market median
+886% vs market
20212025
Asset turnover
0.30×
This company
1.12×
Market median
-73% vs market
20212025
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of M&N Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Petter Sebastian Nåvik | Board of Directors | 0 companies |
| Anna-Sara Cecilia Magnusson | Deputy Board Member | 0 companies |